However, we did not detect significant therapy effects on NCV and CMAP recordings after PXT3003 short-term treatment in CMT1A rats compared to corresponding CMT1A controls (Fig 2D and 2F). This evidence concerns the gene PMP22 and Charcot-Marie-Tooth disease type 1A.